What are the most effective treatments for MRSA infections. How do antibiotics like vancomycin, daptomycin, and ceftaroline combat MRSA. Why is proper antibiotic selection crucial in managing MRSA bacteremia. What role do emerging therapies play in MRSA treatment.

Understanding MRSA and Its Challenges in Treatment

Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that has developed resistance to many common antibiotics, making it particularly challenging to treat. MRSA infections can range from mild skin infections to severe, life-threatening conditions such as bacteremia and endocarditis.

Why is MRSA so difficult to treat? The primary reason lies in its ability to resist multiple antibiotics, including methicillin and other beta-lactam antibiotics. This resistance is due to the presence of the mecA gene, which encodes for a modified penicillin-binding protein (PBP2a) that has a low affinity for beta-lactam antibiotics.

Vancomycin: The Traditional First-line Treatment for MRSA

Vancomycin has long been considered the gold standard for treating MRSA infections. How does vancomycin work against MRSA? It inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, preventing cross-linking of the peptidoglycan layer.

Despite its effectiveness, there are concerns about vancomycin’s efficacy in certain situations. Studies have shown a correlation between higher vancomycin minimum inhibitory concentrations (MICs) and increased mortality in patients with MRSA bloodstream infections. This phenomenon, known as “MIC creep,” has led to debates about optimal dosing strategies and the need for alternative treatments.

Optimizing Vancomycin Therapy

To maximize vancomycin’s effectiveness, clinicians often aim for trough concentrations between 15-20 mg/L for serious MRSA infections. However, research suggests that these targets may not always be optimal. A study by Neely et al. found that current dosing strategies might not achieve the necessary pharmacodynamic targets for all patients.

Are there alternatives to vancomycin for MRSA treatment? Yes, several other antibiotics have shown promise in treating MRSA infections, particularly in cases where vancomycin may be less effective or poorly tolerated.

Daptomycin: A Powerful Alternative for MRSA Bacteremia

Daptomycin is a lipopeptide antibiotic that has gained prominence as an alternative to vancomycin for treating MRSA bacteremia and endocarditis. How does daptomycin differ from vancomycin in its mechanism of action? Daptomycin works by inserting into the bacterial cell membrane, causing rapid depolarization and cell death.

The efficacy of daptomycin in treating MRSA infections has been demonstrated in several clinical studies. A landmark trial by Fowler et al. showed that daptomycin was non-inferior to standard therapy (primarily vancomycin) for S. aureus bacteremia and right-sided endocarditis.

Daptomycin vs. Vancomycin in High-MIC Scenarios

In cases where MRSA isolates have elevated vancomycin MICs, daptomycin may offer advantages. A case-control study by Moore et al. found that daptomycin was associated with better outcomes than vancomycin for MRSA bloodstream infections with high vancomycin MICs. Similarly, Murray et al. reported improved outcomes with early use of daptomycin compared to vancomycin in such cases.

Teicoplanin: An Alternative Glycopeptide for MRSA Treatment

Teicoplanin is another glycopeptide antibiotic that shares structural similarities with vancomycin. How does teicoplanin compare to vancomycin in treating MRSA infections? A Cochrane review by Cavalcanti et al. found no significant difference in efficacy between teicoplanin and vancomycin for proven or suspected infections.

A multicenter prospective observational study by Yoon et al. compared the efficacy and safety of vancomycin versus teicoplanin in patients with healthcare-associated MRSA bacteremia. The study found comparable clinical outcomes between the two antibiotics, suggesting that teicoplanin could be a viable alternative to vancomycin in certain situations.

Emerging Therapies: Telavancin and Ceftaroline

As MRSA continues to evolve, new antibiotics are being developed to combat this challenging pathogen. Two promising agents in this category are telavancin and ceftaroline.

Telavancin: A Novel Lipoglycopeptide

Telavancin is a semisynthetic lipoglycopeptide with a dual mechanism of action against MRSA. How does telavancin work? It inhibits cell wall synthesis and disrupts bacterial membrane integrity, leading to rapid bactericidal activity.

The ASSURE study, a randomized Phase 2 trial by Stryjewski et al., evaluated telavancin versus standard therapy in patients with uncomplicated S. aureus bacteremia. While the study was not powered to show superiority, it demonstrated comparable efficacy between telavancin and standard therapy.

Ceftaroline: A Novel Cephalosporin Active Against MRSA

Ceftaroline is a fifth-generation cephalosporin that has shown activity against MRSA, unlike earlier cephalosporins. What makes ceftaroline effective against MRSA? Its unique ability to bind to PBP2a, the modified penicillin-binding protein responsible for methicillin resistance in MRSA.

A study by Otero et al. elucidated the molecular basis of ceftaroline’s activity against MRSA, showing how it enables allosteric control of PBP2a. This mechanistic insight explains ceftaroline’s effectiveness against MRSA and highlights its potential as a treatment option.

Combination Therapy Approaches for MRSA Infections

In some cases, particularly for severe or persistent MRSA infections, combination therapy may be considered. Are there benefits to using multiple antibiotics for MRSA treatment? Potential advantages include synergistic effects, prevention of resistance development, and improved clinical outcomes in certain scenarios.

Vancomycin plus Beta-lactams

One combination approach that has gained interest is the use of vancomycin in conjunction with beta-lactam antibiotics. How might this combination work against MRSA? The beta-lactam, even if not directly active against MRSA, may enhance vancomycin’s activity through mechanisms such as increased autolysin production or improved vancomycin binding.

Daptomycin plus Beta-lactams

Another promising combination is daptomycin with beta-lactam antibiotics. Studies have shown that this combination can enhance daptomycin’s bactericidal activity against MRSA, potentially overcoming daptomycin non-susceptibility in some cases.

Importance of Antimicrobial Stewardship in MRSA Management

Given the complexity of MRSA treatment and the potential for resistance development, antimicrobial stewardship plays a crucial role in managing these infections. Why is antimicrobial stewardship particularly important for MRSA? It helps ensure appropriate antibiotic use, minimizes the risk of resistance development, and optimizes patient outcomes.

Key Principles of MRSA Antimicrobial Stewardship

• Accurate diagnosis and identification of MRSA infections
• Appropriate selection of initial empiric therapy
• Timely de-escalation based on culture results
• Optimization of antibiotic dosing and duration
• Monitoring for treatment response and adverse effects
• Implementation of infection prevention measures

How can healthcare facilities implement effective antimicrobial stewardship programs for MRSA? Strategies may include developing institutional treatment guidelines, implementing rapid diagnostic techniques, and providing ongoing education for healthcare providers on optimal MRSA management.

Future Directions in MRSA Treatment

As MRSA continues to evolve and present new challenges, ongoing research is crucial to develop novel treatment strategies. What are some promising areas of research in MRSA therapeutics?

Novel Antibiotic Development

Efforts are ongoing to develop new antibiotics with activity against MRSA. Some areas of focus include:

• New classes of antibiotics with unique mechanisms of action
• Engineered antimicrobial peptides
• Antibody-antibiotic conjugates
• Phage therapy

Immunomodulatory Approaches

Can boosting the host immune response help combat MRSA infections? Research is exploring various immunomodulatory strategies, including:

• Vaccines targeting S. aureus virulence factors
• Monoclonal antibodies against specific MRSA antigens
• Immunostimulatory agents to enhance innate immunity

Personalized Treatment Strategies

As our understanding of host-pathogen interactions improves, there is growing interest in personalized approaches to MRSA treatment. How might personalized medicine impact MRSA management? Potential applications include:

• Tailoring antibiotic regimens based on patient-specific factors
• Using biomarkers to predict treatment response and guide therapy
• Incorporating host genetic information to optimize treatment strategies

In conclusion, while MRSA remains a significant challenge in healthcare settings, ongoing research and the development of new treatment strategies offer hope for improved outcomes. As we continue to unravel the complexities of MRSA pathogenesis and antibiotic resistance mechanisms, we can anticipate more targeted and effective therapies in the future.

The management of MRSA infections requires a multifaceted approach, combining judicious use of existing antibiotics, implementation of robust antimicrobial stewardship programs, and continued investment in research and development of novel therapeutic strategies. By staying informed about the latest developments in MRSA treatment and adhering to evidence-based practices, healthcare providers can optimize patient care and contribute to the ongoing fight against antimicrobial resistance.

Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

1. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE. J Rybak M, Talan DA, Chambers HF; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–55. [PubMed] [Google Scholar]

2. Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA. 2014;312:1552–1564. [PubMed] [Google Scholar]

3. Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58:309–316. [PMC free article] [PubMed] [Google Scholar]

4. Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y, Kumar A, Cooperative Antimicrobial Therapy of Septic Shock-CATSS Database Research Group Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents. 2013;41:255–260. [PubMed] [Google Scholar]

5. Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev. 2010:CD007022. [PubMed] [Google Scholar]

6. Yoon YK, Park DW, Sohn JW, Kim HY, Kim YS, Lee CS, Lee MS, Ryu SY, Jang HC, Choi YJ, Kang CI, Choi HJ, Lee SS, Kim SW, Kim SI, Kim ES, Kim JY, Yang KS, Peck KR, Kim MJ. Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-associated methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2014;58:317–324. [PMC free article] [PubMed] [Google Scholar]

7. Karlowsky JA, Nichol K, Zhanel GG. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Clin Infect Dis. 2015;61(Suppl 2):S58–68. [PubMed] [Google Scholar]

8. Stryjewski ME, Lentnek A, O’Riordan W, Pullman J, Tambyah PA, Miró JM, Fowler VG, Jr, Barriere SL, Kitt MM, Corey GR. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis. 2014;14:289. [PMC free article] [PubMed] [Google Scholar]

9. National Institutes of Health. A phase 3 telavancin Staphylococcus aureus (S. Aureus) bacteremia trial. [Accessed June 30 2015]. Available at: https://clinicaltrials.gov/ct2/show/{“type”:”clinical-trial”,”attrs”:{“text”:”NCT02208063″,”term_id”:”NCT02208063″}}NCT02208063.

10. Fowler VG, Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
. N Engl J Med. 2006;355:653–665. [PubMed] [Google Scholar]

11. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38:994–1000. [PubMed] [Google Scholar]

12. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis. 2012;54:51–58. [PubMed] [Google Scholar]

13. Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, Rybak MJ. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis. 2013;56:1562–1569. [PubMed] [Google Scholar]

14. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus
. Clin Infect Dis. 2011;52:1156–1163. [PubMed] [Google Scholar]

15. Otero LH, Rojas-Altuve A, Llarrull LI, Carrasco-López C, Kumarasiri M, Lastochkin E, Fishovitz J, Dawley M, Hesek D, Lee M, Johnson JW, Fisher JF, Chang M, Mobashery S, Hermoso JA. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc Natl Acad Sci USA. 2013;110:16808–16813. [PMC free article] [PubMed] [Google Scholar]

16. Espedido BA, Jensen SO, van Hal SJ. Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia. J Antimicrob Chemother. 2015;70:797–801. [PubMed] [Google Scholar]

17. Vazquez JA, Maggiore CR, Cole P, Smith A, Jandourek A, Friedland HD. Ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. Infect Dis Clin Pract. 2015;23:39–43. [Baltim Md] [PMC free article] [PubMed] [Google Scholar]

18. Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58:2541–2546. [PMC free article] [PubMed] [Google Scholar]

19. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138:135–142. [PubMed] [Google Scholar]

20. Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis. 2006;42:729–730. [PubMed] [Google Scholar]

21. Jang HC, Kim SH, Kim KH, Kim CJ, Lee S, Song KH, Jeon JH, Park WB, Kim HB, Park SW, Kim NJ, Kim EC, Oh MD, Choe KW. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis. 2009;49:395–401. [PubMed] [Google Scholar]

22. Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, Croos-Dabrera RV, Kunkel MJ, Knirsch C. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48:203–212. [PubMed] [Google Scholar]

23. Park HJ, Kim SH, Kim MJ, Lee YM, Park SY, Moon SM, Park KH, Chong YP, Lee SO, Choi SH, Woo JH, Kim YS. Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J Infect. 2012;65:505–512. [PubMed] [Google Scholar]

24. Sánchez García M, De la Torre MA, Morales G, Peláez B, Tolón MJ, Domingo S, Candel FJ, Andrade R, Arribi A, García N, Martínez Sagasti F, Fereres J, Picazo J. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010;303:2260–2264. [PubMed] [Google Scholar]

25. Rybak JM, Marx K, Martin CA. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance. Pharmacotherapy. 2014;34:1198–1208. [PubMed] [Google Scholar]

26. Chan LC, Basuino L, Dip EC, Chambers HF. Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2015;59:3252–3256. [PMC free article] [PubMed] [Google Scholar]

27. Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013;75:331–336. [PubMed] [Google Scholar]

28. Gardiner D, Dukart G, Cooper A, Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis. 2010;50:229–238. [PubMed] [Google Scholar]

29. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57:1756–1762. [PMC free article] [PubMed] [Google Scholar]

30. Dilworth TJ, Ibrahim O, Hall P, Sliwinski J, Walraven C, Mercier RC. beta-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrob Agents Chemother. 2014;58:102–109. [PMC free article] [PubMed] [Google Scholar]

31. Davis JS, Sud A, O’Sullivan MV, Robinson JO, Ferguson PE, Foo H, van Hal SJ, Ralph AP, Howden BP, Binks PM, Kirby A, Tong SY.
Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus (CAMERA) study group; Australasian Society for Infectious Diseases Clinical Research Network. Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62:173–180. [PubMed] [Google Scholar]

32. Chambers HF, Basuino L, Hamilton SM, Choo EJ, Moise P. Daptomycin- β-lactam combinations in a rabbit model of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2016;60:3976–3979. [PMC free article] [PubMed] [Google Scholar]

33. Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014;36:1317–1333. [PubMed] [Google Scholar]

Methicillin-Resistant Staphylococcus Aureus (MRSA)

• “Methicillin-Resistant Staphylococcus aureus” is also available in Portable Document Format (PDF, 47KB, 2pg. )
• Versión en español
• Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA)
• Antibiotic Resistance

What is MRSA?

MRSA refers to a type of bacteria (Staphylococcus aureus) that is resistant to many antibiotics. It is a common cause of hospital-acquired infections.

Who gets MRSA?

Anyone can get MRSA, but it is found most often in hospitalized patients.

What are the symptoms associated with MRSA infection?

MRSA infections can cause a broad range of symptoms depending on the part of the body that is infected. These may include surgical wounds, burns, catheter sites, eye, skin and blood. Infection often results in redness, swelling and tenderness at the site of infection. Sometimes, people may carry MRSA without having any symptoms.

How is it transmitted?

The staph bacteria is generally spread through direct contact with the hands of a health care worker or patient who is infected or carrying the organism.

How long can an infected person carry MRSA?

Some people can carry MRSA for days to many months, even after their infection has been treated.

How are MRSA infections diagnosed?

MRSA infections can be diagnosed when a doctor obtains a sample or specimen from the site of infection and submits it to a laboratory. The laboratory places the specimen on a special “culture” plate containing nutrients, incubates the plate in a warmer and then identifies the bacteria. The final step is for the laboratory to conduct tests using various antibiotics to determine if the bacteria are resistant (able to withstand or tolerate) or sensitive (susceptible to killing) to select antibiotics.

What is the treatment for MRSA?

Although MRSA cannot be effectively treated with antibiotics such as methicillin, nafcillin, cephalosporin or penicillin, it can usually be treated with an antibiotic called vancomycin. Recently, however, a few strains of Staphylococcus aureus have even developed some degree of resistance to vancomycin.